



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BE
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH
SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231 ON 25 September 1998

AGENT/ATTORNEY FOR APPLICANT

DATE

Attorney Docket No. P31158

#8
K. Harmon
10/22/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Vere Hodge et al. 25 September 1998
Serial No.: 08/945,249 Group Art Unit No.: 1614
Filed: 2 February 1998 Examiner: R. Travers
For: Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of
Viral Diseases

TRANSMITTAL LETTER

Transmitted herewith is an Amendment in the above-identified application.

EXTENSION OF TIME PETITION

Applicants hereby petition for an extension of time for response from the date of the Examiner's
action as needed, the fee being as follows:

(X)	one month extension.....	\$ 110
()	two months extension.....	\$ 400
()	three months extension.....	\$ 950
()	four months extension (not beyond statutory time period).....	\$1510

Charge \$110.00 to Deposit Account No. 19-2570. Two copies of this form are enclosed.

Please charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this
paper, or credit any overpayment, to Deposit Account No. 19-2570. Also, should the Patent and
Trademark Office determine that the fee calculated in the above extension petition is not deemed
sufficient to have this response considered as being timely filed, this constitutes a petition for extension
of time for the minimum period to effect timely filing, and the Commissioner is authorized to debit any
necessary fee to said deposit account.

Respectfully submitted,

Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017
Facsimile (610) 270-5090
n:\dl\oa\us\31158\31158ext.doc

10/07/1998 RTSEGRYE 00000003 192570 08945249
01 FC:115 110.00 CH



Attorney Docket No. P31158

INTERNATIONAL APP. NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP96/01706	April 23, 1996	April 24, 1995

TITLE OF INVENTION

Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases

APPLICANT(S) FOR DO/US

Richard Anthony Vere Hodge and Raymond F. Schinazi

PRELIMINARY AMENDMENT

Applicants respectfully request that the following amendments and remarks be made of record prior to examination of the above-cited application.

IN THE CLAIMS:

Please cancel claim 2.

Please amend the following claims:

Claim 4 (amended). [A] The method [, composition, or use] according to Claim 1 [, 2, or 3] wherein the (R)-PCV-TP is in the form of a bioprecursor which is a derivative of (R)- PCV-MP which liberates intracellularly (R)-PCV-MP which is in turn converted to (R)-PCV-TP.

Claim 5 (amended). A compound which is a bioprecursor of (R)-PCV-TP [, for use in the method, use, or composition according to claim 1, 2, 3, or 4].

Please add the following claim:

Claim 8. The composition according to Claim 3 wherein the (R)-PCV-TP is in the form of a bioprecursor which is a derivative of (R)- PCV-MP which liberates intracellularly (R)-PCV-MP which is in turn converted to (R)-PCV-TP.

Claim 9. The compound according to Claim 5 wherein the bioprecursor h is a derivative of (R)- PCV-MP which liberates intracellularly (R)-PCV-MP which is in turn converted to (R)-PCV-TP.

- 2 -

Claim 10. The compound according to Claim 7 which is a PL-ASOR derivative.

Claim 11. The compound according to Claim 7 which is a phospholipid derivative.

Claim 12. The compound according to Claim 7 which is a (R)-MP Bis(POM) derivative.

Claim 13. The compound according to Claim 7 which is a (R)-MP diphenyl ester derivative.

Claim 14. The compound according to Claim 7 which is a dimyristoylglycerol diphosphate derivative.

REMARKS

Claim 2 has been cancelled. Claims 4 and 5 have been amended to correspond more closely to U.S. practice, and Claims 8 to 14 have been added. Support for the newly added claims lie in originally filed claims, and are added to correspond to U.S. practice. No new matter is believed added.

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

SmithKline Beecham Corp.
Corp. Intellectual Property (UW2220)
P.O. Box 1539
King of Prussia, PA 19406-0939
(610) 270-5017 - telephone
(610) 270-5090 - facsimile
n:\dld\oa\us\31158pre.doc



CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN
AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF
PATENTS, WASHINGTON, D.C. 20231, ON 25 September 1998

AGENT/ATTORNEY FOR APPLICANT

DATE

P31158

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Vere Hodge et al. 25 September 1998
Serial No.: 08/945,249 Group Art Unit No.: 1614
Filed: 2 February 1998 Examiner: R. Travers
For: Use of (R)-Penciclovir Triphosphate For the Manufacture of A
Medicament For the Treatment of Viral Diseases

Assistant Commissioner of Patents
Washington, D.C. 20231

RESPONSE

Sir:

In response to the Examiner's Action mailed 3 August 1998, having a shortened statutory period of thirty (30) days, please enter the following Remarks and Amendments into the record. Also enclosed herewith is a petition for a one (1) month extension of the shortened statutory period set by the Examiner and authorization to charge the required fee to the indicated deposit account.

In the Claims:

Please amend the following claims:

Claim 1 (amended). A method of treatment of:

- i) HIV-1 infections in mammals, including humans; or
- ii) HBV infections in mammals, including humans;

which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A):

San 10/18
9/30
Harmon
10/24/98
11/24/98

RECEIVED
98 OCT - 7 PM 2: 06
GROUP 180

B1